WellPoint Planning to Stop Covering Lipitor

Health-insurer WellPoint Inc. is planning to stop covering Pfizer Inc.’s Lipitor cholesterol-lowering pills for millions of members in favor of generic versions, marking a new challenge to Pfizer’s efforts to fend off generic competition to its best-selling drug.  WellPoint, one of the nation’s largest managed-care firms, will make the change on April 1 for many commercial pharmacy-benefit members in 12 of the 14 states it serves.


This entry was posted in Industry Updates, Manufacturers Updates. Bookmark the permalink.

Comments are closed.